Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N1-(2-amino-4-methylpentyl)octahydro-pyrrolo[1,2-a]pyrimidine is a synthetic small molecule with the molecular formula C13H27N3 and a molecular weight of approximately 225.37 g/mol. It belongs to the class of organoheterocyclic compounds known as diazinanes and features a pyrrolopyrimidine core structure. The compound is considered experimental and has not been approved for any therapeutic use or entered clinical trials beyond preclinical investigation. Its mechanism of action and pharmacological targets are not described in publicly available sources; no information on its biological activity or intended indication is currently available.[1][3][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N1-(2-amino-4-methylpentyl)octahydro-pyrrolo[1,2-a]pyrimidine.